tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Health Catalyst price target lowered to $5 from $9 at Canaccord

Canaccord analyst Richard Close lowered the firm’s price target on Health Catalyst (HCAT) to $5 from $9 and keeps a Buy rating on the shares. The firm updated its model following Q2 results and following the company’s annual Health Analytics Summit they walked away from their time with management and clients encouraged by the direction Health Catalyst is heading. That is, shifting the business to high-margin technology and less reliance on lower-margin Professional services as AI technology is more heavily integrated into the company’s offerings.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1